肿瘤细胞簇中177Lu与161Tb的膜与核吸收剂量:细胞异质性与双靶向潜在获益的蒙特卡罗研究
采用蒙特卡罗代码CELLDOSE评估19细胞簇中177Lu与161Tb在细胞膜、细胞质或细胞核分布时的膜与核吸收剂量,并模拟4个细胞未被标记的异质性靶向及双靶向。161Tb的膜和核吸收剂量分别较177Lu高2至6倍和2至3倍;异质性靶向使未标记细胞吸收剂量明显降低,双靶向有助于减少剂量异质性。
要点
- 161Tb对细胞膜和细胞核的吸收剂量分别较177Lu高2至6倍和2至3倍。
- 4个细胞未被表面靶向时,其膜吸收剂量仅为均匀靶向时的9.6%(177Lu)和2.9%(161Tb)。
- 双靶向有助于减少吸收剂量异质性,作者建议在临床前和临床研究中探索。
核心结论
- 为根除肿瘤细胞簇,161Tb可能比177Lu是更好的候选核素。
- 异质性细胞靶向可导致吸收剂量显著异质。
- 双靶向有助于降低剂量异质性,作者建议在临床前和临床研究中探索。
研究设计与样本
- 使用蒙特卡罗代码CELLDOSE评估19细胞簇(细胞直径14微米、细胞核直径10微米)中177Lu与161Tb的膜与核吸收剂量。
- 考虑放射性核素分布于细胞表面、细胞质内或细胞核内,每个标记细胞释放1,436 MeV。
- 为模拟异质性靶向,19个细胞中4个未标记,其位置随机确定;模拟单靶向及两种放射性药物靶向不同靶点的双靶向。
主要发现
- 161Tb对细胞膜的吸收剂量较177Lu高2至6倍,对细胞核的吸收剂量较177Lu高2至3倍。
- 全部19个细胞被靶向时,膜与核吸收剂量主要取决于放射性核素位置。
- 核素位于细胞表面时,膜吸收剂量显著高于核吸收剂量:177Lu为38-41 Gy vs 4.7-7.2 Gy,161Tb为237-244 Gy vs 9.8-15.1 Gy。
- 4个细胞未被细胞表面放射性药物靶向时,其膜平均吸收剂量仅为均匀靶向时的9.6%(177Lu)和2.9%(161Tb),对核吸收剂量影响中等。
- 核素位于细胞核内时,未标记细胞的核吸收剂量仅为均匀靶向时的17%(177Lu)和10.8%(161Tb)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early use of targeted radionuclide therapy to eradicate tumor cell clusters and micrometastases might offer cure. However, there is a need to select appropriate radionuclides and assess the potential impact of heterogeneous targeting. Methods: The Monte Carlo code CELLDOSE was used to assess membrane and nuclear absorbed doses from 177Lu and 161Tb (β--emitter with additional conversion and Auger electrons) in a cluster of 19 cells (14-μm diameter, 10-μm nucleus). The radionuclide distributions considered were cell surface, intracytoplasmic, or intranuclear, with 1,436 MeV released per labeled cell. To model heterogeneous targeting, 4 of the 19 cells were unlabeled, their position being stochastically determined. We simulated situations of single targeting, as well as dual targeting, with the 2 radiopharmaceuticals aiming at different targets. Results: 161Tb delivered 2- to 6-fold higher absorbed doses to cell membranes and 2- to 3-fold higher nuclear doses than 177Lu. When all 19 cells were targeted, membrane and nuclear absorbed doses were dependent mainly on radionuclide location. With cell surface location, membrane absorbed doses were substantially higher than nuclear absorbed doses, both with 177Lu (38-41 vs. 4.7-7.2 Gy) and with 161Tb (237-244 vs. 9.8-15.1 Gy). However, when 4 cells were not targeted by the cell surface radiopharmaceutical, the membranes of these cells received on average only 9.6% of the 177Lu absorbed dose and 2.9% of the 161Tb dose, compared with a cluster with uniform cell targeting, whereas the impact on nuclear absorbed doses was moderate. With an intranuclear radionuclide location, the nuclei of unlabeled cells received only 17% of the 177Lu absorbed dose and 10.8% of the 161Tb dose, compared with situations with uniform targeting. With an intracytoplasmic location, nuclear and membrane absorbed doses to unlabeled cells were one half to one quarter those obtained with uniform targeting, both for 177Lu and for 161Tb. Dual targeting was beneficial in minimizing absorbed dose heterogeneities. Conclusion: To eradicate tumor cell clusters, 161Tb may be a better candidate than 177Lu. Heterogeneous cell targeting can lead to substantial heterogeneities in absorbed doses. Dual targeting was helpful in reducing dose heterogeneity and should be explored in preclinical and clinical studies.
引用
- Larouze A, Alcocer-Ávila M, Morgat C, et al. Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting-A Monte Carlo Study. J Nucl Med. 2023. PMID: 37321819. doi:10.2967/jnumed.123.265509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。